A Japan Phase I/II Study of Bortezomib in Relapsed or Refractory Multiple Myeloma Patients

NCT00752518 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

35

Enrollment

INDUSTRY

Sponsor class

Conditions

Refractory
Multiple Myeloma
Relapse

Interventions

DRUG: bortezomib

Sponsor

Janssen Pharmaceutical K.K.